Search / Trial NCT00000932

A Study of the Long-Term Outcomes of HIV-Positive Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of May 23, 2024

Completed

Keywords

Prospective Studies Hiv 1 Drug Therapy, Combination Drug Resistance, Microbial Cd4 Lymphocyte Count Disease Progression Treatment Outcome Genotype Anti Hiv Agents Viral Load

Description

Highly active antiretroviral therapy (HAART) often results in short-term benefits for people with HIV in terms of reduced plasma viral levels and increased CD4 cell counts. When used at an early stage of HIV disease, however, the clinical benefit of HAART is uncertain. Many questions still remain regarding the optimal use of antiretroviral therapies, such as the timing of initial antiretroviral therapy and the composition of the best combination regimen to use initially or after virologic failure. Randomized trials of different starting antiretroviral regimens (e.g., FIRST [CPCRA 058]), dif...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Are 13 years of age or older (consent of parent or guardian required if under the age of 18).
  • Are HIV-positive.
  • Have either: (1) no previous experience with anti-HIV treatment (defined as no previous protease inhibitor or nonnucleoside reverse transcriptase inhibitor use, 1 week or less of lamivudine use, and 4 weeks or less of cumulative nucleoside reverse transcriptase inhibitor use) or (2) current or previous enrollment in a qualifying CPCRA study.

Attachments

readout_NCT00000932_2024-05-23.pdf

4.5 MB

NCT00000932_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Chicago, Illinois, United States

Denver, Colorado, United States

Mill Valley, California, United States

Oakland, California, United States

Oakland, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

San Francisco, California, United States

Boulder, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Denver, Colorado, United States

Wheat Ridge, Colorado, United States

Farmington, Connecticut, United States

New Haven, Connecticut, United States

New Haven, Connecticut, United States

Washington, District Of Columbia, United States

Washington, District Of Columbia, United States

Washington, District Of Columbia, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Baton Rouge, Louisiana, United States

Baton Rouge, Louisiana, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

Boston, Massachusetts, United States

Springfield, Massachusetts, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Camden, New Jersey, United States

Hillsborough, New Jersey, United States

Neptune, New Jersey, United States

Newark, New Jersey, United States

Newark, New Jersey, United States

Paterson, New Jersey, United States

Perth Amboy, New Jersey, United States

Randolph, New Jersey, United States

Union, New Jersey, United States

Voorhees, New Jersey, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Portland, Oregon, United States

Portland, Oregon, United States

Portland, Oregon, United States

Portland, Oregon, United States

Portland, Oregon, United States

Portland, Oregon, United States

Portland, Oregon, United States

Salem, Oregon, United States

Salem, Oregon, United States

Philadelphia, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Mechanicsville, Virginia, United States

Norfolk, Virginia, United States

Petersburg, Virginia, United States

Richmond, Virginia, United States

Richmond, Virginia, United States

Richmond, Virginia, United States

Richmond, Virginia, United States

Richmond, Virginia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Throughout study

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0